Literature DB >> 32126143

Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status.

Raksha Shrestha1, Mamiko Sakata-Yanagimoto2, Koichiro Maie1, Motohiko Oshima3,4, Masatomo Ishihara1, Yasuhito Suehara1, Kota Fukumoto1, Yaeko Nakajima-Takagi3,4, Hirotaka Matsui5, Takayasu Kato2, Hideharu Muto1,2, Tatsuhiro Sakamoto2, Manabu Kusakabe2, Yasuhito Nannya6, Hideki Makishima6, Hiroo Ueno6, Ryunosuke Saiki6, Seishi Ogawa6,7,8, Kenichi Chiba9, Yuichi Shiraishi9, Satoru Miyano10, Enguerran Mouly11, Olivier A Bernard11, Toshiya Inaba12, Haruhiko Koseki13, Atsushi Iwama3,4, Shigeru Chiba2.   

Abstract

Loss-of-function mutations in ten-eleven translocation-2 (TET2) are recurrent events in acute myeloid leukemia (AML) as well as in preleukemic hematopoietic stem cells (HSCs) of age-related clonal hematopoiesis. TET3 mutations are infrequent in AML, but the level of TET3 expression in HSCs has been found to decline with age. We examined the impact of gradual decrease of TET function in AML development by generating mice with Tet deficiency at various degrees. Tet2f/f and Tet3f/f mice were crossed with mice expressing Mx1-Cre to generate Tet2f/wtTet3f/fMx-Cre+ (T2ΔT3), Tet2f/fTet3f/wtMx-Cre+ (ΔT2T3), and Tet2f/fTet3f/fMx-Cre+ (ΔT2ΔT3) mice. All ΔT2ΔT3 mice died of aggressive AML at a median survival of 10.7 weeks. By comparison, T2ΔT3 and ΔT2T3 mice developed AML at longer latencies, with a median survival of ∼27 weeks. Remarkably, all 9 T2ΔT3 and 8 ΔT2T3 mice with AML showed inactivation of the remaining nontargeted Tet2 or Tet3 allele, respectively, owing to exonic loss in either gene or stop-gain mutations in Tet3. Recurrent mutations other than Tet3 were not noted in any mice by whole-exome sequencing. Spontaneous inactivation of residual Tet2 or Tet3 alleles is a recurrent genetic event during the development of AML with Tet insufficiency.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32126143      PMCID: PMC7065477          DOI: 10.1182/bloodadvances.2019001324

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  44 in total

1.  Age-Dependent Decrease of DNA Hydroxymethylation in Human T Cells.

Authors:  Thien Phu Truong; Mamiko Sakata-Yanagimoto; Momoko Yamada; Genta Nagae; Terukazu Enami; Rie Nakamoto-Matsubara; Hiroyuki Aburatani; Shigeru Chiba
Journal:  J Clin Exp Hematop       Date:  2015

Review 2.  Connections between TET proteins and aberrant DNA modification in cancer.

Authors:  Yun Huang; Anjana Rao
Journal:  Trends Genet       Date:  2014-08-14       Impact factor: 11.639

3.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

4.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

Authors:  Anna M Jankowska; Hadrian Szpurka; Ramon V Tiu; Hideki Makishima; Manuel Afable; Jungwon Huh; Christine L O'Keefe; Rebecca Ganetzky; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

5.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

6.  TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.

Authors:  Cristina Pérez; Nicolas Martínez-Calle; José Ignacio Martín-Subero; Victor Segura; Eric Delabesse; Marta Fernandez-Mercado; Leire Garate; Sara Alvarez; José Rifon; Sara Varea; Jacqueline Boultwood; James S Wainscoat; Juan Cruz Cigudosa; María José Calasanz; Nicholas C P Cross; Felipe Prósper; Xabier Agirre
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.752

7.  Age-related mutations associated with clonal hematopoietic expansion and malignancies.

Authors:  Mingchao Xie; Charles Lu; Jiayin Wang; Michael D McLellan; Kimberly J Johnson; Michael C Wendl; Joshua F McMichael; Heather K Schmidt; Venkata Yellapantula; Christopher A Miller; Bradley A Ozenberger; John S Welch; Daniel C Link; Matthew J Walter; Elaine R Mardis; John F Dipersio; Feng Chen; Richard K Wilson; Timothy J Ley; Li Ding
Journal:  Nat Med       Date:  2014-10-19       Impact factor: 53.440

8.  CopywriteR: DNA copy number detection from off-target sequence data.

Authors:  Thomas Kuilman; Arno Velds; Kristel Kemper; Marco Ranzani; Lorenzo Bombardelli; Marlous Hoogstraat; Ekaterina Nevedomskaya; Guotai Xu; Julian de Ruiter; Martijn P Lolkema; Bauke Ylstra; Jos Jonkers; Sven Rottenberg; Lodewyk F Wessels; David J Adams; Daniel S Peeper; Oscar Krijgsman
Journal:  Genome Biol       Date:  2015-02-27       Impact factor: 13.583

9.  Deorphanization and characterization of the ectopically expressed olfactory receptor OR51B5 in myelogenous leukemia cells.

Authors:  S Manteniotis; S Wojcik; J R Göthert; J Dürig; U Dührsen; G Gisselmann; H Hatt
Journal:  Cell Death Discov       Date:  2016-05-09

10.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

View more
  5 in total

Review 1.  Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.

Authors:  Kanak Joshi; Lei Zhang; Peter Breslin S J; Ameet R Kini; Jiwang Zhang
Journal:  J Exp Clin Cancer Res       Date:  2022-10-07

Review 2.  Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate.

Authors:  Andrew B Das; Carlos C Smith-Díaz; Margreet C M Vissers
Journal:  Haematologica       Date:  2021-01-01       Impact factor: 9.941

3.  A mosaic analysis system with Cre or Tomato expression in the mouse.

Authors:  Qun Wang; Yen-Yu Lin; Baojun Zhang; Jianxuan Wu; Sumedha Roy; Jeremy J Ratiu; Yanping Xu; Meifang Dai; Laura P Hale; Yue Xiong; Qi-Jing Li; Yuan Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-26       Impact factor: 11.205

Review 4.  TET2: A cornerstone in normal and malignant hematopoiesis.

Authors:  Hiroyoshi Kunimoto; Hideaki Nakajima
Journal:  Cancer Sci       Date:  2020-11-18       Impact factor: 6.518

Review 5.  Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia.

Authors:  Sagarajit Mohanty; Michael Heuser
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.